**Question:** The main side effect of Imatinib mesylate

A. Gastrointestinal disturbances
B. Skin rashes
C. Hepatic dysfunction
D. Hypothyroidism

**Core Concept:** Imatinib mesylate is an oral anticancer medication primarily used in the treatment of chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST). It is a tyrosine kinase inhibitor that targets the BCR-ABL fusion protein.

**Why the Correct Answer is Right:** The main side effect of Imatinib mesylate is gastrointestinal disturbances due to its action on the gastrointestinal tract. This may lead to nausea, vomiting, diarrhea, abdominal pain, and weight loss. The medication is commonly taken with food to minimize gastrointestinal side effects.

**Why Each Wrong Option is Incorrect:**

B. Skin rashes (Option B) are a relatively rare side effect of Imatinib mesylate and should not be confused with the more common gastrointestinal disturbances.

C. Hepatic dysfunction (Option C) is a less common side effect, but not the main side effect. Imatinib mesylate is primarily associated with gastrointestinal side effects, not liver-related issues.

D. Hypothyroidism (Option D) is also a rare side effect, not the main side effect. Imatinib mesylate does not have a significant impact on thyroid function in comparison to its gastrointestinal side effects.

**Clinical Pearl:** It is essential for medical students, residents, and practicing physicians to be aware of the common side effects of Imatinib mesylate to appropriately counsel patients and manage their expectations regarding potential adverse reactions. While gastrointestinal disturbances are the main side effect, other rare side effects (e.g., skin rashes, hepatic dysfunction, and hypothyroidism) should also be recognized for accurate patient care.